The Week in Review 18 March 2016 Save

See the highlights from the past week that appeared on RheumNow.com, and watch Dr. Jack Cush as he reviews each of them. 

1. NSAID use in Knee Osteoarthritis associated w/ incr risk venous thromboembolism; for all NSAIDs but not naproxen 
2. Metanalysis shows there is no link between Leflunomide use in RA and Lung disease. 
3. In a 6 mos RCT, Febuxostat slows the decline in GFR in CKD stages 3/4 compared to placebo. 
4. RA Annual cost of biologics (2011-13) RTX $19,569, ABA $21,877, ETN $25,805, CZP $26,285, GOL $27,666, ADA $30,269 
5. Rheumatic Dz adm to ICU: vasculitis(36%), sarcoidosis (14%), PSS (10%), SLE (8%) for infx(60%) & organ failure(48%). 
6. The Role of Hydroxychloroquine Blood Levels in SLE 
7. Bisphosphonate Use Falls Following FDA Warnings  
8. Acetaminophen: No Effect in Osteoarthritis Pain or Function  
9. Sclerostin Inhibition May Worsen Rheumatoid Arthritis 
10. TNF Inhibitors Increase Perioperative Infection Risk 
11. New CDC Guidelines on Prescribing Opiates for Pain